img

Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection is such a human immunoglobulin for intravenous injection that is made from healthy plasma by cold ethanal protein fractionation and purification, eliminating anticomplementary activity, both through eliminating and deactivating the virus. It contains a proper quantity of stabilizer, and contains no preservatives or antibiotics.
Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market is projected to reach US$ 6235.2 million in 2029, increasing from US$ 4560 million in 2022, with the CAGR of 4.5% during the period of 2024 to 2029. Demand from Hospitals and Clinics are the major drivers for the industry.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Takeda Pharmaceutical
Baxter International Inc.
CSL Behring
Bayer AG
Grifols, S.A.
Octapharma AG
Taibang Biologic Group
Pacific Shuanglin Bio-pharmacy
Shenzhen Weiguang Biological Products
Nanjing Pharmacare Co.,Ltd
Shanghai RAAS
Harbin Pacific Biopharmaceutical
Hualan Biological Engineering Inc.
China Biologic Products, Inc.
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
Boya Bio-Pharmaceutical Group Co., Ltd.
ADMA Biologics, Inc.
Sinopharm Group Co., Ltd.
Segment by Type
1.25g
2.5g
5g
Others

Segment by Application


Hospitals
Clinics
Others

Segment by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection introduction, etc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Overview
1.1 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Overview
1.2 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Segment by Type
1.2.1 1.25g
1.2.2 2.5g
1.2.3 5g
1.2.4 Others
1.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Type
1.3.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Overview by Type (2018-2029)
1.3.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Historic Market Size Review by Type (2018-2024)
1.3.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Type (2018-2024)
1.4.2 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Type (2018-2024)
2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Competition by Company
2.1 Global Top Players by Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (2018-2024)
2.2 Global Top Players by Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue (2018-2024)
2.3 Global Top Players by Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Price (2018-2024)
2.4 Global Top Manufacturers Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Base Distribution, Sales Area, Product Type
2.5 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Competitive Situation and Trends
2.5.1 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection as of 2022)
2.7 Date of Key Manufacturers Enter into Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market
2.8 Key Manufacturers Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Status and Outlook by Region
3.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Historic Market Size by Region
3.2.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Volume by Region (2018-2024)
3.2.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Value by Region (2018-2024)
3.2.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Forecasted Market Size by Region
3.3.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Volume by Region (2024-2029)
3.3.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Value by Region (2024-2029)
3.3.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection by Application
4.1 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Segment by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Others
4.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Application
4.2.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Overview by Application (2018-2029)
4.2.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Historic Market Size Review by Application (2018-2024)
4.2.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Application (2018-2024)
4.3.2 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Breakdown by Application (2018-2024)
5 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection by Country
5.1 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Historic Market Size by Country
5.1.1 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Volume by Country (2018-2024)
5.1.3 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Value by Country (2018-2024)
5.2 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Forecasted Market Size by Country
5.2.1 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Volume by Country (2024-2029)
5.2.2 North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Value by Country (2024-2029)
6 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection by Country
6.1 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Historic Market Size by Country
6.1.1 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Volume by Country (2018-2024)
6.1.3 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Value by Country (2018-2024)
6.2 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Forecasted Market Size by Country
6.2.1 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Volume by Country (2024-2029)
6.2.2 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Value by Country (2024-2029)
7 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection by Region
7.1 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Historic Market Size by Region
7.1.1 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Forecasted Market Size by Region
7.2.1 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Value by Region (2024-2029)
8 Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection by Country
8.1 Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Historic Market Size by Country
8.1.1 Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Volume by Country (2018-2024)
8.1.3 Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Value by Country (2018-2024)
8.2 Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Forecasted Market Size by Country
8.2.1 Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Volume by Country (2024-2029)
8.2.2 Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Value by Country (2024-2029)
9 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection by Country
9.1 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Historic Market Size by Country
9.1.1 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Forecasted Market Size by Country
9.2.1 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Takeda Pharmaceutical
10.1.1 Takeda Pharmaceutical Company Information
10.1.2 Takeda Pharmaceutical Introduction and Business Overview
10.1.3 Takeda Pharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Takeda Pharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered
10.1.5 Takeda Pharmaceutical Recent Development
10.2 Baxter International Inc.
10.2.1 Baxter International Inc. Company Information
10.2.2 Baxter International Inc. Introduction and Business Overview
10.2.3 Baxter International Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Baxter International Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered
10.2.5 Baxter International Inc. Recent Development
10.3 CSL Behring
10.3.1 CSL Behring Company Information
10.3.2 CSL Behring Introduction and Business Overview
10.3.3 CSL Behring Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2018-2024)
10.3.4 CSL Behring Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered
10.3.5 CSL Behring Recent Development
10.4 Bayer AG
10.4.1 Bayer AG Company Information
10.4.2 Bayer AG Introduction and Business Overview
10.4.3 Bayer AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Bayer AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered
10.4.5 Bayer AG Recent Development
10.5 Grifols, S.A.
10.5.1 Grifols, S.A. Company Information
10.5.2 Grifols, S.A. Introduction and Business Overview
10.5.3 Grifols, S.A. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Grifols, S.A. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered
10.5.5 Grifols, S.A. Recent Development
10.6 Octapharma AG
10.6.1 Octapharma AG Company Information
10.6.2 Octapharma AG Introduction and Business Overview
10.6.3 Octapharma AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Octapharma AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered
10.6.5 Octapharma AG Recent Development
10.7 Taibang Biologic Group
10.7.1 Taibang Biologic Group Company Information
10.7.2 Taibang Biologic Group Introduction and Business Overview
10.7.3 Taibang Biologic Group Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Taibang Biologic Group Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered
10.7.5 Taibang Biologic Group Recent Development
10.8 Pacific Shuanglin Bio-pharmacy
10.8.1 Pacific Shuanglin Bio-pharmacy Company Information
10.8.2 Pacific Shuanglin Bio-pharmacy Introduction and Business Overview
10.8.3 Pacific Shuanglin Bio-pharmacy Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Pacific Shuanglin Bio-pharmacy Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered
10.8.5 Pacific Shuanglin Bio-pharmacy Recent Development
10.9 Shenzhen Weiguang Biological Products
10.9.1 Shenzhen Weiguang Biological Products Company Information
10.9.2 Shenzhen Weiguang Biological Products Introduction and Business Overview
10.9.3 Shenzhen Weiguang Biological Products Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Shenzhen Weiguang Biological Products Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered
10.9.5 Shenzhen Weiguang Biological Products Recent Development
10.10 Nanjing Pharmacare Co.,Ltd
10.10.1 Nanjing Pharmacare Co.,Ltd Company Information
10.10.2 Nanjing Pharmacare Co.,Ltd Introduction and Business Overview
10.10.3 Nanjing Pharmacare Co.,Ltd Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Nanjing Pharmacare Co.,Ltd Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered
10.10.5 Nanjing Pharmacare Co.,Ltd Recent Development
10.11 Shanghai RAAS
10.11.1 Shanghai RAAS Company Information
10.11.2 Shanghai RAAS Introduction and Business Overview
10.11.3 Shanghai RAAS Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Shanghai RAAS Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered
10.11.5 Shanghai RAAS Recent Development
10.12 Harbin Pacific Biopharmaceutical
10.12.1 Harbin Pacific Biopharmaceutical Company Information
10.12.2 Harbin Pacific Biopharmaceutical Introduction and Business Overview
10.12.3 Harbin Pacific Biopharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Harbin Pacific Biopharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered
10.12.5 Harbin Pacific Biopharmaceutical Recent Development
10.13 Hualan Biological Engineering Inc.
10.13.1 Hualan Biological Engineering Inc. Company Information
10.13.2 Hualan Biological Engineering Inc. Introduction and Business Overview
10.13.3 Hualan Biological Engineering Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2018-2024)
10.13.4 Hualan Biological Engineering Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered
10.13.5 Hualan Biological Engineering Inc. Recent Development
10.14 China Biologic Products, Inc.
10.14.1 China Biologic Products, Inc. Company Information
10.14.2 China Biologic Products, Inc. Introduction and Business Overview
10.14.3 China Biologic Products, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2018-2024)
10.14.4 China Biologic Products, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered
10.14.5 China Biologic Products, Inc. Recent Development
10.15 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
10.15.1 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Company Information
10.15.2 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Introduction and Business Overview
10.15.3 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2018-2024)
10.15.4 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered
10.15.5 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Recent Development
10.16 Boya Bio-Pharmaceutical Group Co., Ltd.
10.16.1 Boya Bio-Pharmaceutical Group Co., Ltd. Company Information
10.16.2 Boya Bio-Pharmaceutical Group Co., Ltd. Introduction and Business Overview
10.16.3 Boya Bio-Pharmaceutical Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2018-2024)
10.16.4 Boya Bio-Pharmaceutical Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered
10.16.5 Boya Bio-Pharmaceutical Group Co., Ltd. Recent Development
10.17 ADMA Biologics, Inc.
10.17.1 ADMA Biologics, Inc. Company Information
10.17.2 ADMA Biologics, Inc. Introduction and Business Overview
10.17.3 ADMA Biologics, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2018-2024)
10.17.4 ADMA Biologics, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered
10.17.5 ADMA Biologics, Inc. Recent Development
10.18 Sinopharm Group Co., Ltd.
10.18.1 Sinopharm Group Co., Ltd. Company Information
10.18.2 Sinopharm Group Co., Ltd. Introduction and Business Overview
10.18.3 Sinopharm Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2018-2024)
10.18.4 Sinopharm Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered
10.18.5 Sinopharm Group Co., Ltd. Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industrial Chain Analysis
11.4 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Dynamics
11.4.1 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Trends
11.4.2 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Drivers
11.4.3 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Challenges
11.4.4 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Distributors
12.3 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of 1.25g
Table 2. Major Company of 2.5g
Table 3. Major Company of 5g
Table 4. Major Company of Others
Table 5. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2018-2024) & (K Units)
Table 7. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Type (2018-2024)
Table 8. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2018-2024) & (US& Million)
Table 9. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Share in Value by Type (2018-2024)
Table 10. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Price by Type (2018-2024) & (US$/Unit)
Table 11. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2024-2029) & (K Units)
Table 12. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Type (2024-2029)
Table 13. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2024-2029) & (US$ Million)
Table 14. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Type (2024-2029)
Table 15. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Price by Type (2024-2029) & (US$/Unit)
Table 16. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2018-2024) & (K Units)
Table 17. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2018-2024) & (US$ Million)
Table 18. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units) by Type (2018-2024)
Table 19. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2018-2024) & (US$ Million)
Table 20. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units) by Type (2018-2024)
Table 21. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2018-2024) & (US$ Million)
Table 22. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units) by Type (2018-2024)
Table 23. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2018-2024) & (US$ Million)
Table 24. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units) by Type (2018-2024)
Table 25. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2018-2024) & (US$ Million)
Table 26. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Company (2018-2024) & (K Units)
Table 27. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Share by Company (2018-2024)
Table 28. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Company (2018-2024) & (US$ Million)
Table 29. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Share by Company (2018-2024)
Table 30. Global Market Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Price by Company (2018-2024) & (US$/Unit)
Table 31. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 32. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 33. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection as of 2022)
Table 34. Date of Key Manufacturers Enter into Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market
Table 35. Key Manufacturers Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Type
Table 36. Mergers & Acquisitions, Expansion Plans
Table 37. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region (2018-2024) & (K Units)
Table 39. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Region (2018-2024)
Table 40. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region (2018-2024) & (US$ Million)
Table 41. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Region (2018-2024)
Table 42. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 43. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region (2024-2029) & (K Units)
Table 44. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Region (2024-2029)
Table 45. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region (2024-2029) & (US$ Million)
Table 46. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Region (2024-2029)
Table 47. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2029)
Table 48. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 49. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2018-2024) & (K Units)
Table 50. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Application (2018-2024)
Table 51. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2018-2024) & (US$ Million)
Table 52. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Application (2018-2024)
Table 53. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Price by Application (2018-2024) & (US$/Unit)
Table 54. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2024-2029) & (K Units)
Table 55. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Application (2024-2029)
Table 56. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2024-2029) & (US$ Million)
Table 57. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Application (2024-2029)
Table 58. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Price by Application (2024-2029) & (US$/Unit)
Table 59. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2018-2024) (K Units)
Table 60. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2018-2024) & (US$ Million)
Table 61. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2018-2024) (K Units)
Table 62. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2018-2024) & (US$ Million)
Table 63. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2018-2024) (K Units)
Table 64. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2018-2024) & (US$ Million)
Table 65. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2018-2024) (K Units)
Table 66. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2018-2024) & (US$ Million)
Table 67. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2018-2024) (K Units)
Table 68. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2018-2024) & (US$ Million)
Table 69. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2018-2024) & (K Units)
Table 70. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Country (2018-2024)
Table 71. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2018-2024) & (US$ Million)
Table 72. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Country (2018-2024)
Table 73. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2024-2029) & (K Units)
Table 74. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Country (2024-2029)
Table 75. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2024-2029) & (US$ Million)
Table 76. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Country (2024-2029)
Table 77. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2018-2024) & (K Units)
Table 78. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Country (2018-2024)
Table 79. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2018-2024) & (US$ Million)
Table 80. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Country (2018-2024)
Table 81. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2024-2029) & (K Units)
Table 82. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Country (2024-2029)
Table 83. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2024-2029) & (US$ Million)
Table 84. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Country (2024-2029)
Table 85. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region (2018-2024) & (K Units)
Table 86. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Region (2018-2024)
Table 87. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region (2018-2024) & (US$ Million)
Table 88. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Region (2018-2024)
Table 89. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region (2024-2029) & (K Units)
Table 90. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Region (2024-2029)
Table 91. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region (2024-2029) & (US$ Million)
Table 92. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Region (2024-2029)
Table 93. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2018-2024) & (K Units)
Table 94. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Country (2018-2024)
Table 95. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2018-2024) & (US$ Million)
Table 96. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Country (2018-2024)
Table 97. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2024-2029) & (K Units)
Table 98. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Country (2024-2029)
Table 99. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2024-2029) & (US$ Million)
Table 100. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Country (2024-2029)
Table 101. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2018-2024) & (K Units)
Table 102. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Country (2018-2024)
Table 103. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2018-2024) & (US$ Million)
Table 104. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Country (2018-2024)
Table 105. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2024-2029) & (K Units)
Table 106. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Country (2024-2029)
Table 107. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2024-2029) & (US$ Million)
Table 108. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Country (2024-2029)
Table 109. Takeda Pharmaceutical Company Information
Table 110. Takeda Pharmaceutical Introduction and Business Overview
Table 111. Takeda Pharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 112. Takeda Pharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product
Table 113. Takeda Pharmaceutical Recent Development
Table 114. Baxter International Inc. Company Information
Table 115. Baxter International Inc. Introduction and Business Overview
Table 116. Baxter International Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 117. Baxter International Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product
Table 118. Baxter International Inc. Recent Development
Table 119. CSL Behring Company Information
Table 120. CSL Behring Introduction and Business Overview
Table 121. CSL Behring Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 122. CSL Behring Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product
Table 123. CSL Behring Recent Development
Table 124. Bayer AG Company Information
Table 125. Bayer AG Introduction and Business Overview
Table 126. Bayer AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 127. Bayer AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product
Table 128. Bayer AG Recent Development
Table 129. Grifols, S.A. Company Information
Table 130. Grifols, S.A. Introduction and Business Overview
Table 131. Grifols, S.A. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 132. Grifols, S.A. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product
Table 133. Grifols, S.A. Recent Development
Table 134. Octapharma AG Company Information
Table 135. Octapharma AG Introduction and Business Overview
Table 136. Octapharma AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 137. Octapharma AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product
Table 138. Octapharma AG Recent Development
Table 139. Taibang Biologic Group Company Information
Table 140. Taibang Biologic Group Introduction and Business Overview
Table 141. Taibang Biologic Group Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 142. Taibang Biologic Group Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product
Table 143. Taibang Biologic Group Recent Development
Table 144. Pacific Shuanglin Bio-pharmacy Company Information
Table 145. Pacific Shuanglin Bio-pharmacy Introduction and Business Overview
Table 146. Pacific Shuanglin Bio-pharmacy Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 147. Pacific Shuanglin Bio-pharmacy Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product
Table 148. Pacific Shuanglin Bio-pharmacy Recent Development
Table 149. Shenzhen Weiguang Biological Products Company Information
Table 150. Shenzhen Weiguang Biological Products Introduction and Business Overview
Table 151. Shenzhen Weiguang Biological Products Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 152. Shenzhen Weiguang Biological Products Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product
Table 153. Shenzhen Weiguang Biological Products Recent Development
Table 154. Nanjing Pharmacare Co.,Ltd Company Information
Table 155. Nanjing Pharmacare Co.,Ltd Introduction and Business Overview
Table 156. Nanjing Pharmacare Co.,Ltd Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 157. Nanjing Pharmacare Co.,Ltd Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product
Table 158. Nanjing Pharmacare Co.,Ltd Recent Development
Table 159. Shanghai RAAS Company Information
Table 160. Shanghai RAAS Introduction and Business Overview
Table 161. Shanghai RAAS Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 162. Shanghai RAAS Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product
Table 163. Shanghai RAAS Recent Development
Table 164. Harbin Pacific Biopharmaceutical Company Information
Table 165. Harbin Pacific Biopharmaceutical Introduction and Business Overview
Table 166. Harbin Pacific Biopharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 167. Harbin Pacific Biopharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product
Table 168. Harbin Pacific Biopharmaceutical Recent Development
Table 169. Hualan Biological Engineering Inc. Company Information
Table 170. Hualan Biological Engineering Inc. Introduction and Business Overview
Table 171. Hualan Biological Engineering Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 172. Hualan Biological Engineering Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product
Table 173. Hualan Biological Engineering Inc. Recent Development
Table 174. China Biologic Products, Inc. Company Information
Table 175. China Biologic Products, Inc. Introduction and Business Overview
Table 176. China Biologic Products, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 177. China Biologic Products, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product
Table 178. China Biologic Products, Inc. Recent Development
Table 179. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Company Information
Table 180. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Introduction and Business Overview
Table 181. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 182. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product
Table 183. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Recent Development
Table 184. Boya Bio-Pharmaceutical Group Co., Ltd. Company Information
Table 185. Boya Bio-Pharmaceutical Group Co., Ltd. Introduction and Business Overview
Table 186. Boya Bio-Pharmaceutical Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 187. Boya Bio-Pharmaceutical Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product
Table 188. Boya Bio-Pharmaceutical Group Co., Ltd. Recent Development
Table 189. ADMA Biologics, Inc. Company Information
Table 190. ADMA Biologics, Inc. Introduction and Business Overview
Table 191. ADMA Biologics, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 192. ADMA Biologics, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product
Table 193. ADMA Biologics, Inc. Recent Development
Table 194. Sinopharm Group Co., Ltd. Company Information
Table 195. Sinopharm Group Co., Ltd. Introduction and Business Overview
Table 196. Sinopharm Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 197. Sinopharm Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product
Table 198. Sinopharm Group Co., Ltd. Recent Development
Table 199. Key Raw Materials Lists
Table 200. Raw Materials Key Suppliers Lists
Table 201. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Trends
Table 202. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Drivers
Table 203. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Challenges
Table 204. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Restraints
Table 205. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Distributors List
Table 206. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Downstream Customers
Table 207. Research Programs/Design for This Report
Table 208. Key Data Information from Secondary Sources
Table 209. Key Data Information from Primary Sources
List of Figures
Figure 1. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Picture
Figure 2. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Status and Outlook (2018-2029) & (US$ Million)
Figure 4. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Status and Outlook (2018-2029) & (K Units)
Figure 5. Product Picture of 1.25g
Figure 6. Global 1.25g Sales YoY Growth (2018-2029) & (K Units)
Figure 7. Product Picture of 2.5g
Figure 8. Global 2.5g Sales YoY Growth (2018-2029) & (K Units)
Figure 9. Product Picture of 5g
Figure 10. Global 5g Sales YoY Growth (2018-2029) & (K Units)
Figure 11. Product Picture of Others
Figure 12. Global Others Sales YoY Growth (2018-2029) & (K Units)
Figure 13. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2018-2029) & (US$ Million)
Figure 14. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Type in 2022 & 2029
Figure 15. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Type in 2022
Figure 16. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Type in 2022
Figure 17. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Type in 2022
Figure 18. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Type in 2022
Figure 19. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Type in 2022
Figure 20. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Type in 2022
Figure 21. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Type in 2022
Figure 22. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Type in 2022
Figure 23. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Type in 2022
Figure 24. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Type in 2022
Figure 25. The 5 and 10 Largest Manufacturers in the World: Market Share by Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales in 2022
Figure 26. The 5 and 10 Largest Manufacturers in the World: Market Share by Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue in 2022
Figure 27. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 28. Product Picture of Hospitals
Figure 29. Global Hospitals Sales YoY Growth (2018-2029) & (K Units)
Figure 30. Product Picture of Clinics
Figure 31. Global Clinics Sales YoY Growth (2018-2029) & (K Units)
Figure 32. Product Picture of Others
Figure 33. Global Others Sales YoY Growth (2018-2029) & (K Units)
Figure 34. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2018-2029) & (US$ Million)
Figure 35. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Application in 2022 & 2029
Figure 36. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Application in 2022
Figure 37. North America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Application in 2022
Figure 38. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Application in 2022
Figure 39. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Application in 2022
Figure 40. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Application in 2022
Figure 41. Asia-Pacific Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Application in 2022
Figure 42. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Volume by Application in 2022
Figure 43. Latin America Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Application in 2022
Figure 44. Middle East and Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share in Value by Application in 2022
Figure 45. Key Raw Materials Price
Figure 46. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Cost Structure
Figure 47. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries